Charles River Laboratories International (NYSE:CRL) Given Hold Rating at Argus

Argus reiterated their hold rating on shares of Charles River Laboratories International (NYSE:CRL) in a research note issued to investors on Friday morning, Marketbeat.com reports.

CRL has been the subject of several other reports. TheStreet raised shares of Charles River Laboratories International from a c+ rating to a b- rating in a report on Friday, March 1st. Mizuho started coverage on shares of Charles River Laboratories International in a report on Friday, June 7th. They issued a neutral rating and a $235.00 price objective for the company. Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating for the company in a report on Friday, May 10th. TD Cowen lowered their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a hold rating on the stock in a research note on Monday, May 13th. Finally, StockNews.com cut shares of Charles River Laboratories International from a buy rating to a hold rating in a research note on Friday, June 14th. Eight investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Charles River Laboratories International currently has an average rating of Hold and a consensus price target of $254.50.

Charles River Laboratories International Stock Down 0.4 %

CRL opened at $206.51 on Friday. The company has a 50 day moving average of $220.16 and a 200 day moving average of $232.48. The company has a market cap of $10.64 billion, a PE ratio of 24.30, a price-to-earnings-growth ratio of 1.96 and a beta of 1.40. Charles River Laboratories International has a 12 month low of $161.65 and a 12 month high of $275.00. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 EPS for the quarter, topping the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, sell-side analysts expect that Charles River Laboratories International will post 11 EPS for the current year.

Insider Activity

In other news, EVP Joseph W. Laplume sold 1,304 shares of the firm’s stock in a transaction on Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the sale, the executive vice president now owns 23,276 shares in the company, valued at approximately $5,282,953.72. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently made changes to their positions in the stock. VisionPoint Advisory Group LLC raised its position in shares of Charles River Laboratories International by 105.7% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock valued at $28,000 after buying an additional 74 shares in the last quarter. Headlands Technologies LLC purchased a new position in Charles River Laboratories International in the 1st quarter worth $41,000. Brown Brothers Harriman & Co. raised its position in Charles River Laboratories International by 76.0% in the 4th quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock worth $52,000 after purchasing an additional 95 shares during the period. Sunbelt Securities Inc. raised its position in Charles River Laboratories International by 1,072.7% in the 1st quarter. Sunbelt Securities Inc. now owns 258 shares of the medical research company’s stock worth $70,000 after purchasing an additional 236 shares during the period. Finally, Concord Wealth Partners raised its position in Charles River Laboratories International by 362.5% in the 1st quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock worth $70,000 after purchasing an additional 203 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).